Regulatory Blog

The European Medicines Agency (EMA) continues to strengthen transparency, data sharing, and international regulatory collaboration through its Clinical Data Publication (CDP) framework. A key development in this area is the introduction of a work-share initiative with Health Canada (HC) under Policy 0070, aimed at improving efficiency while maintaining robust safeguards for sensitive information. The guidance Clinical Data Publication (CDP): Questions and Answers on EMA Polic

The UK clinical trial regulatory framework is undergoing a major transformation with the implementation of updated ICH E6 (R3) Good Clinical Practice (GCP) principles, alongside new guidance on quality, risk proportionality, and clinical investigations. The guidance Clinical trials for medicines: Compliance with ICH E6 Good Clinical Practice (GCP) in the United Kingdom, Clinical trials for medicines: guidance on quality and risk proportionality, and Clinical investigations fo

The regulatory landscape for advanced therapies and patient access in the United States continues to evolve, with the FDA issuing updated guidances in April 2026 that address both cutting-edge genome editing safety and patient access to investigational treatments . Together, these guidances highlight the balance between innovation, safety evaluation, and ethical access to therapies across the product lifecycle. The guidance Safety Assessment of Genome Editing in Human Gene

The Guidance on the electronic submission of information on investigational medicinal products for human use in the Extended EudraVigilance medicinal product dictionary (XEVMPD) was updated on 13 April 2026 (Version 1.5) , providing detailed procedural and technical instructions for sponsors submitting clinical trial product data. Introduction This guidance provides consolidated instructions for sponsors on how to electronically submit information on investigational medici

The European regulatory landscape continues to evolve with a strong focus on supporting innovation in rare diseases and ensuring safe, evidence-based development of medicines for children . The European Medicines Agency (EMA) has issued two key procedural guidelines: Procedural advice for orphan medicinal product designation – Guidance for sponsors Procedural advice on paediatric applications – Guidance for applicants together, establish a comprehensive regulatory framewo

The UK regulatory framework for clinical trials is undergoing a significant transition with the adoption of updated Good Clinical Practice (GCP) standards aligned with international expectations. The Medicines and Healthcare products Regulatory Agency (MHRA) is reinforcing compliance with ICH E6 (R3) to ensure high standards of participant safety, data integrity, and efficient trial conduct. The guidance Clinical trials for medicines: Guidance on compliance with ICH E6 Good

The UK regulatory system for medicines continues to advance towards faster access, aligned decision-making, and patient-focused innovation . The Medicines and Healthcare products Regulatory Agency (MHRA) is strengthening its national procedures to ensure efficient evaluation of medicines while improving coordination with health technology assessment bodies. The guidance National assessment procedure for medicines was updated on 9 April 2026 , including the addition of a webi

The guidance Incorporating Voluntary Patient Preference Information over the Total Product Life Cycle was issued on 30 March 2026 , updating and superseding the earlier 2016 guidance, and providing comprehensive recommendations on how patient preferences can inform benefit-risk assessments. The FDA recognizes that patients living with diseases or conditions develop first-hand insights into treatment benefits and risks. Their perspectives can play a critical role in evaluatin

The UK regulatory landscape for medicines is increasingly evolving to integrate environmental protection alongside public health safety, and recently, on 1 April 2026, the UK MHRA updated its guidance on " Environmental Risk Assessments in medicines " . A key component of this approach is the requirement for Environmental Risk Assessments (ERA), ensuring that medicinal products do not pose unintended risks to ecosystems during their lifecycle. Background Environmental Risk

India’s Central Drugs Standard Control Organization (CDSCO) has released a draft notification dated 09 March 2026 proposing amendments to the Drugs Rules, 1945 to establish a structured framework for managing post-approval manufacturing changes. This draft notification introduces clear regulatory requirements for notifying authorities when manufacturers make changes to manufacturing processes, excipients, packaging, shelf life, specifications, testing procedures, or docume

This guidance , published in March 2026 by the European Directorate for the Quality of Medicines & HealthCare (EDQM) , introduces new approaches for accelerating the assessment of Certificates of Suitability (CEP) applications. It focuses on two key pathways: Fast-track assessment Reliance-based assessment Both approaches aim to improve regulatory efficiency, reduce delays, and ensure timely access to medicines. CEP procedures are essential for demonstrating that a substance

This guidance, " Submitting an application for review by the ACBS, " explains how to submit an application to the Advisory Committee on Borderline Substances (ACBS) . The ACBS evaluates products that may be considered borderline between foods and medicines, particularly for use within the NHS. The guidance provides a structured approach to ensure that applications are complete, accurate, and suitable for review. Purpose of the Application Process The purpose of this guidanc

This guidance, " Archiving and retention of clinical trial records, " explains the requirements for archiving and retaining clinical trial records. Proper archiving is essential to ensure that trial data remains accessible, accurate, and verifiable over time. It supports regulatory compliance and ensures that clinical trials can be reviewed, inspected, or audited when required. Purpose of Archiving and Retention The purpose of this guidance is to ensure that essential cli

This guidance , " Clinical Trials Regulations enforcement provisions , " explains how regulatory authorities enforce compliance in clinical trials. Its primary focus is to ensure that trials are conducted in a way that protects participant safety, rights, and data integrity. It supports the implementation of the Medicines for Human Use (Clinical Trials) Regulations, ensuring that all trials meet required legal and ethical standards. Purpose of Enforcement Provisions The purp

The development of biosimilar and interchangeable biological products is an important part of improving access to biological medicines. To support this process, the U.S. Food and Drug Administration (FDA) has issued guidance documents that clarify regulatory expectations under the Biologics Price Competition and Innovation Act (BPCI Act) . Two key FDA guidance documents provide detailed explanations through a question-and-answer format to help sponsors understand the regulat

Regulatory authorities across the European Union continue to strengthen pharmacovigilance systems and data-driven regulatory decision-making. Two important EMA documents highlight these developments: the EU implementation strategy for the ICH E2D(R1) guideline on post-approval safety data and the Network Data Steering Group (NDSG) Workplan 2026–2028 on data and artificial intelligence in medicines regulation. Guidance: Network Data Steering Group Workplan 2026–2028: Data and

Clinical trials play a critical role in evaluating the safety and effectiveness of medicines before they are made available to patients. In the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) provides guidance to help sponsors and researchers comply with regulatory requirements for clinical trials involving medicinal products. This article provides a consolidated overview of MHRA guidance covering several key areas of clinical trial regulation,

The U.S. Food and Drug Administration (FDA) has issued guidance documents to help pharmaceutical manufacturers understand regulatory expectations related to market exclusivity for drug products and responses to inspection findings following CGMP inspections . These guidances support transparency in regulatory processes and help industry ensure compliance with quality and development requirements. Guidance: New Clinical Investigation Exclusivity (3-Year Exclusivity) for Drug

This blog summarizes two important regulatory guidances from the U.S. Food and Drug Administration (FDA) that support pharmacovigilance and real-world evidence generation: M14: General Principles for Planning, Designing, Analyzing, and Reporting Non-Interventional Studies E2D(R1): Post-approval Safety Data – Definitions and Standards for Management and Reporting of Individual Case Safety Reports Together, these guidances provide a framework for how pharmaceutical companies ge

The U.S. Food and Drug Administration (FDA) has issued a final rule titled “ Revising the National Drug Code Format and Drug Label Barcode Requirements .” This rule introduces a uniform 12-digit National Drug Code (NDC) format to standardize how drugs marketed in the United States are identified. The National Drug Code is an FDA standard used to uniquely identify drug products marketed in the U.S. Currently, the NDC assigned by FDA is a 10-digit number , and it may appear i